Top

Published in:

01-03-2017 | Original Research

Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial

Authors: Ashok Reddy, MD, MS, Tiffany L. Huseman, BA, Anne Canamucio, MS, Steven C. Marcus, PhD, David A. Asch, MD, MBA, Kevin Volpp, MD PhD, Judith A. Long, MD

Published in: Journal of General Internal Medicine | Issue 3/2017

Abstract

Background

Simple nudges such as reminders and feedback reports to either a patient or a partner may facilitate improved medication adherence.

Objective

To test the impact of a pill bottle used to monitor adherence, deliver a daily alarm, and generate weekly medication adherence feedback reports on statin adherence.

Design

Three-month, three-arm randomized clinical trial (ClinicalTrials.gov identifier: NCT02480530).

Participants

One hundred and twenty-six veterans with known coronary artery disease and poor adherence (medication possession ratio <80 %).

Intervention

Patients were randomized to one of three groups: (1) a control group (n = 36) that received a pill-monitoring device with no alarms or feedback; (2) an individual feedback group (n = 36) that received a daily alarm and a weekly medication adherence feedback report; and (3) a partner feedback group (n = 54) that received an alarm and a weekly feedback report that was shared with a friend, family member, or a peer. The intervention continued for 3 months, and participants were followed for an additional 3 months after the intervention period.

Main Measures

Adherence as measured by pill bottle. Secondary outcomes included change in LDL (mg/dl), patient activation, and social support.

Key Results

During the 3-month intervention period, medication adherence was higher in both feedback arms than in the control arm (individual feedback group 89 %, partner feedback group 86 %, control group 67 %; p < 0.001 and = 0.001). At 6 months, there was no difference in medication adherence between either of the feedback groups and the control (individual feedback 60 %, partner feedback 52 %, control group 54 %; p = 0.75 and 0.97).

Conclusions

Daily alarms combined with individual or partner feedback reports improved statin medication adherence. While neither an individual feedback nor partner feedback strategy created a sustainable medication adherence habit, the intervention itself is relatively easy to implement and low cost.

Available only for authorised users

CTT Collaborators (CTT). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. doi:10.1016/S0140-6736(05)67394-1.CrossRef

Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.CrossRefPubMed

Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.CrossRefPubMed

Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86. doi:10.1001/jama.297.2.177.CrossRefPubMed

Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart Br Card Soc. 2002;88(3):229–33.CrossRef

Patel MS, Asch DA, Volpp KG. Wearable devices as facilitators, not drivers, of health behavior change. JAMA. 2015;313(5):459–60. doi:10.1001/jama.2014.14781.CrossRefPubMed

Volpp KG, Loewenstein G, Troxel AB, et al. A test of financial incentives to improve warfarin adherence. BMC Health Serv Res. 2008;8(1):272.CrossRefPubMedPubMedCentral

Petry NM, et al. Financial reinforcers for improving medication adherence: findings from a meta-analysis. Am J Med. 2012;125(9):888–96.CrossRefPubMedPubMedCentral

Halpern SD, Madison KM, Volpp KG. Patients as mercenaries? The ethics of using financial incentives in the war on unhealthy behaviors. Circ Cardiovasc Qual Outcomes. 2009;2(5):514–6. doi:10.1161/CIRCOUTCOMES.109.871855.CrossRefPubMedPubMedCentral

10.

Pearson SD, Lieber SR. Financial penalties for the unhealthy? Ethical guidelines for holding employees responsible for their health. Health Aff. 2009;28(3):845–52. doi:10.1377/hlthaff.28.3.845.CrossRef

11.

Cialdini RB, Goldstein NJ. Social influence: compliance and conformity. Annu Rev Psychol. 2004;55:591–621. doi:10.1146/annurev.psych.55.090902.142015.CrossRefPubMed

12.

Darby S, et al. The effectiveness of feedback on energy consumption. Rev DEFRA Lit Metering Billing Direct Disp. 2006;486:2006.

13.

Kessler J, Zhang C. Behavioral Economics and Health. Oxford Textbook of Public Health. Oxford Press; 2014. http://assets.wharton.upenn.edu/~juddk/papers/KesslerZhang_BehavioralEconomicsHealth.pdf. Accessed 13 Jan 2016.

14.

Long JA, Jahnle EC, Richardson DM, Loewenstein G, Volpp KG. Peer mentoring and financial incentives to improve glucose control in African American veterans: a randomized trial. Ann Intern Med. 2012;156(6):416–24.CrossRefPubMedPubMedCentral

15.

Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H. Antiretroviral therapy in resource-poor settings: decreasing barriers to access and promoting adherence. J Acquir Immune Defic Syndr. 2006;43:S123–6.CrossRefPubMed

16.

Duhigg C. The Power of Habit: Why We Do What We Do in Life and Business. Vol 34. Random House; 2012.

17.

Lally P, Van Jaarsveld CH, Potts HW, Wardle J. How are habits formed: modelling habit formation in the real world. Eur J Soc Psychol. 2010;40(6):998–1009.CrossRef

18.

Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.CrossRefPubMed

19.

Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38(9):1363–8.CrossRefPubMed

20.

Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4p1):1005–26.CrossRefPubMedPubMedCentral

21.

Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30–41.CrossRef

22.

Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41(1):295–301.CrossRefPubMed

23.

Vervloet M, Linn AJ, van Weert JCM, de Bakker DH, Bouvy ML, van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012;19(5):696–704. doi:10.1136/amiajnl-2011-000748.CrossRefPubMedPubMedCentral

24.

Reese PP, et al. Two randomized controlled pilot trials of social forces to improve statin adherence among patients with diabetes. J Gen Intern Med. 2015; 1–9.

25.

Chi MD, et al. Adherence to statins and LDL-cholesterol goal attainment. Am J Manag Care. 2014;20(4):e105–12.PubMed

Title: Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial
Authors: Ashok Reddy, MD, MS
Tiffany L. Huseman, BA
Anne Canamucio, MS
Steven C. Marcus, PhD
David A. Asch, MD, MBA
Kevin Volpp, MD PhD
Judith A. Long, MD
Publication date: 01-03-2017
Publisher: Springer US
Published in: Journal of General Internal Medicine / Issue 3/2017
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-016-3858-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Design

Participants

Intervention

Main Measures

Key Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2017

Isolation Precautions for Hospitalized Patients: The Challenges of Identifying Unintended Individual Consequences and Measuring the Prevention of Community Harm

The Effect of Hospital Isolation Precautions on Patient Outcomes and Cost of Care: A Multi-Site, Retrospective, Propensity Score-Matched Cohort Study

Primary care providers’ cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda

An Abscess of Urachal Remnant

Defining Team Effort Involved in Patient Care from the Primary Care Physician’s Perspective

Who Gets Testosterone? Patient Characteristics Associated with Testosterone Prescribing in the Veteran Affairs System: a Cross-Sectional Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials